Cepheid Plans to Buy Plastics Firm, Signs Second Agreement to Increase Adoption of TB Test | GenomeWeb

NEW YORK (GenomeWeb News) – One day after saying that its third-quarter revenues would fail to meet expectations, Cepheid said on Thursday that it is acquiring a plastics company and bringing at least some of its molding operations in-house.

Company officials also said that the firm has signed the second of three agreements aimed at increasing adoption of its Xpert MTB/RIF test in resource-poor areas of the world with multi-drug-resistant tuberculosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.